FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 346:855-856 March 14, 2002 Number 11 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Schneeweiss, S. Related Article by Lewis, J. H. PubMed Citation

It is not surprising that spending for prescription drugs is the fastest-growing component of health care in the United States. Just 12 years ago, prescription drugs accounted for 6 percent of total spending on personal health. Today, drugs account for over 9 percent of health spending, and the projections suggest that they could account for 14 percent by 2010.¹ Why this rapid growth? Much has been written about the high prices charged for prescription drugs, and there is no question that the medications new to the market in the past few years are expensive. But the real story is the . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Minhas, R., Patel, K. C. (2008). From rationing to rational: the evolving status of NICE. JRSM 101: 436-442 [Full Text]  
• Siracuse, M. V., Clark, B. E., Garis, R. I. (2008). Undocumented source of pharmacy benefit manager revenue. Am J Health Syst Pharm 65: 552-557 [Abstract] [Full Text]  
• Mayes, R., Hester, B. (2004). Value-Based Drug Rationing. Health Aff (Millwood) 23: 282-282 [Full Text]  
• Tunis, S. R., Stryer, D. B., Clancy, C. M. (2003). Practical Clinical Trials: Increasing the Value of Clinical Research for Decision Making in Clinical and Health Policy. JAMA 290: 1624-1632 [Abstract] [Full Text]